Danaher
DHR
Market cap $146B

203.68 USD

-0.31

0.15%

Updated Jul 31, 9:57 AM EDT

1 day

-0.15%

5 days

0.07%

1 month

3.11%

3 months

2.18%

6 months

-8.56%

Year to date

-11.37%

1 year

-26.49%

5 years

12.74%

10 years

230.97%

About: In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Employees: 63,000

Healthcare Diagnostics & Research

0

Funds holding %

of 7,323 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

120% more call options, than puts

Call options by funds: $1.53B | Put options by funds: $697M

4% more funds holding in top 10

Funds holding in top 10: 57 [Q4 2024] → 59 (+2) [Q1 2025]

0.31% less ownership

Funds ownership: 79.06% [Q4 2024] → 78.74% (-0.31%) [Q1 2025]

4% less funds holding

Funds holding: 2,281 [Q4 2024] → 2,179 (-102) [Q1 2025]

12% less capital invested

Capital invested by funds: $131B [Q4 2024] → $115B (-$16B) [Q1 2025]

17% less repeat investments, than reductions

Existing positions increased: 788 | Existing positions reduced: 953

28% less first-time investments, than exits

New positions opened: 152 | Existing positions closed: 211

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$205

1%

upside

Avg. target

$234

15%

upside

High target

$275

35%

upside

7 analyst ratings

6 positive

86%

1 neutral

14%

0 negative

0%

UBS Dan Leonard	10%upside $225	Buy Maintained	23 Jul 2025
Wells Fargo Brandon Couillard	1%upside $205	Equal-Weight Maintained	23 Jul 2025
Guggenheim Subbu Nambi	23%upside $250	Buy Reiterated	23 Jul 2025
Baird Catherine Schulte	12%upside $229	Outperform Maintained	23 Jul 2025
Scotiabank Sung Ji Nam	35%upside $275	Sector Outperform Upgraded	11 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 20 articles about DHR published over the past 30 days

The Motley Fool

Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever

Often, great investing boils down to holding on to great stocks. It can be as simple as that.

Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever

Zacks Investment Research

International Markets and Danaher (DHR): A Deep Dive for Investors

Explore how Danaher's (DHR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

International Markets and Danaher (DHR): A Deep Dive for Investors

CNBC Television

Investors decided the good outweighs the bad with Danaher, says Jim Cramer

'Mad Money' host Jim Cramer talks how to play Danaher after earnings.

Investors decided the good outweighs the bad with Danaher, says Jim Cramer

Danaher Q2 2025 Update

While the worst seem to be behind them, the business isn't quite humming enough to get investors excited yet. Revenue growth guidance for 2025 remains unchanged at 3%. But they did raise full year adjusted diluted net EPS guidance to a range of $7.70 to $7.80 vs previous range of $7.60 to $7.75. Compared to the past few years, Danaher's multiples have noticeably come down. However, it is hard for a stock to go up if revenue growth hovers around LSD level.

Danaher Q2 2025 Update

Zacks Investment Research

CVS or DHR: Which Is the Better Value Stock Right Now?

Investors interested in Medical Services stocks are likely familiar with CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?

CVS or DHR: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Here's Why Danaher (DHR) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Danaher (DHR) is a Strong Growth Stock

Danaher Stock: Attractively Valued And Poised For Growth Acceleration

Danaher Corporation is returning to growth, led by strong bioprocessing demand and resilient diagnostics, with Life Sciences expected to recover in late 2025. Margins may face short-term pressure, but a $150M cost-reduction plan and easing China headwinds should drive margin expansion from FY26 onward. The stock trades at a meaningful discount to historical valuation, offering compelling upside as earnings growth is set to reaccelerate post-FY25.

Danaher Stock: Attractively Valued And Poised For Growth Acceleration

The Motley Fool

Danaher Raises 2025 Earnings Outlook

Danaher (DHR 0.98%) reported its second-quarter 2025 results on July 22, 2025, with sales of $5.9 billion and core revenue growth of 1.5% year over year. Adjusted diluted EPS grew 5% to $1.80, free cash flow hit $1.1 billion, and management raised full-year adjusted diluted net EPS guidance to $7.70–$7.80.

Danaher Raises 2025 Earnings Outlook

The Motley Fool

Danaher Beats Q2 Revenue, EPS Forecasts

Global science and technology innovator Danaher (DHR 1.08%) reported second quarter 2025 results on Tuesday, July 22, that topped analysts' consensus expectations. Q2 revenue of $5.94 billion came in above the $5.84 billion estimate, and adjusted EPS reached $1.80 versus the $1.64 analysts expected.

Danaher Beats Q2 Revenue, EPS Forecasts

Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript

Danaher Corporation (NYSE:DHR ) Q2 2025 Earnings Conference Call July 22, 2025 8:00 AM ET Company Participants John Bedford - Vice President of Investor Relations Matthew R. McGrew - CFO & Executive VP Rainer M.

Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™